<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2972">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778946</url>
  </required_header>
  <id_info>
    <org_study_id>121759</org_study_id>
    <nct_id>NCT01778946</nct_id>
  </id_info>
  <brief_title>Nicotine Treatment of Cognitive Decline in Down Syndrome</brief_title>
  <official_title>Nicotinic Treatment of Age-Related Cognitive Decline in Down Syndrome: An Open Label Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will ascertain whether nicotine is safe and tolerable in DS patients, help with&#xD;
      dose-ranging of nicotine in DS, look for evidence of enhancements in cognitive functioning,&#xD;
      and establish evidence for biological and behavioral correlates of nicotinic stimulation&#xD;
      effects. The knowledge gained from the translational aspects of this project may also guide&#xD;
      the application of new nicotinic drugs in DS and generate, for the first time, data on the&#xD;
      importance of nicotinic receptor changes in the development of cognitive impairment in DS&#xD;
      adults.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        -  Transdermal nicotine treatment will be well tolerated out to one month by non-smoking DS&#xD;
           patients without significant adverse effects.&#xD;
&#xD;
        -  Nicotine will enhance cognitive performance by one month compared to baseline and&#xD;
           post-treatment testing.&#xD;
&#xD;
        -  Nicotine will enhance functioning detectable by clinician and/or informant ratings&#xD;
           (pre-post).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 50% of adults with Down Syndrome (DS) develop Alzheimer's disease (AD) by the age of 60&#xD;
      (Nadel 2003), and life expectancy in DS is now 50-60 years. Thus, age-associated cognitive&#xD;
      impairment and dementia in older adults with DS is an urgent public health concern. The&#xD;
      investigators propose that nicotinic stimulation is a promising strategy to stabilize or&#xD;
      improve cognitive functioning in adults with DS, possibly with additional neuroprotective&#xD;
      effects. The investigators have extensive experience investigating the role of nicotinic&#xD;
      receptors on human cognition and impairment. This application takes advantage of new insights&#xD;
      into treating Mild Cognitive Impairment (MCI-the precursor condition to Alzheimer's Disease&#xD;
      (AD) in typically developing individuals) with nicotine to propose an open label pilot study&#xD;
      of transdermal nicotine in middle-aged non-smoking DS patients who show early cognitive&#xD;
      and/or behavioral changes consistent with MCI/dementia.&#xD;
&#xD;
      The goal of this study is to establish preliminary evidence for safety, gain preliminary&#xD;
      evidence as to whether nicotine enhances cognitive functioning in DS adults, and examine&#xD;
      electrophysiological, biological, and behavioral correlates of nicotinic stimulation effects.&#xD;
&#xD;
      The investigators propose that positive results on cognitive or functional indices that would&#xD;
      lead to a larger and longer double-blind trial to test more definitively whether nicotinic&#xD;
      stimulation may be cognitively and/or functionally enhancing for DS patients. The knowledge&#xD;
      gained from the translational aspects of this project will guide the development of&#xD;
      potentially new nicotinic drugs in DS and generate, for the first time, data on the&#xD;
      importance of nicotinic receptor changes in the development of cognitive impairment in DS&#xD;
      adults. This work also represents the first time that cutting-edge advances in treating&#xD;
      MCI/AD in the general population are immediately and rigorously applied to those with DS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of Nicotine Intervention</measure>
    <time_frame>1 Month</time_frame>
    <description>Maximum transdermal nicotine dosage able to be maintained stably by participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Improvement - Simple Response Time</measure>
    <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
    <description>Psychomotor speed was measured by the performance on the CANTAB simple reaction time task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory - Event-Related Potentials</measure>
    <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
    <description>The investigators will measure daily low-moderate dose nicotine treatment's changes to electrophysiological markers of memory performance using an incidental memory task. The incidental memory task consists of presenting participants with a series of 60 complex images, 50 of which are presented once, and 10 which are repeated 5 times each. The task measures the presence of the late positive potential (LPP), a positive deflection over the parietal cortex which is elevated for the repeated compared to the singly presented images. The presence of this potential is indicative of improved recognition memory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Improvement - Continuous Performance Test</measure>
    <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
    <description>Performance on the Conners' Continuous Performance Test, which is a measure of sustained attention. The main outcome measure was commission errors, which measures attention failures. The commission errors are calculated as T-scores. Higher T-scores indicate worse performance, lower T-scores indicate better performance. Average performance is a score of 50, with a standard deviation of 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Improvement - Buschke Selective Reminding Task</measure>
    <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
    <description>Episodic memory performance was assessed by the Buschke Selective Reminding Task. The main outcome metric of this test was the total words correctly recalled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Improvement - Critical Flicker Fusion Task</measure>
    <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
    <description>Arousal and vigilance were measured by the Critical Flicker Fusion task. The task used at perceptual performance on ascending and descending frequencies of the task.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Nicotine (7mg)</intervention_name>
    <arm_group_label>Nicotine</arm_group_label>
    <other_name>Transdermal Nicotine Patch</other_name>
    <other_name>Nicotine Skin Patch</other_name>
    <other_name>Adhesive Nicotine Patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moderate Dose Nicotine (14mg)</intervention_name>
    <arm_group_label>Nicotine</arm_group_label>
    <other_name>Transdermal Nicotine Patch</other_name>
    <other_name>Nicotine Skin Patch</other_name>
    <other_name>Adhesive Nicotine Patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cognitive complaints and/or memory difficulties which are verified as new onset by an&#xD;
             informant.&#xD;
&#xD;
          -  Cognitive Global Rating consistent with mild impairment or deterioration from&#xD;
             premorbid baseline.&#xD;
&#xD;
          -  General cognition and functional performance sufficiently preserved such that a&#xD;
             diagnosis of Alzheimer's disease/dementia cannot be made by the physician at the time&#xD;
             of the screening visit.&#xD;
&#xD;
          -  No significant cerebrovascular disease: Modified Hachinski score of less than or equal&#xD;
             to 4.&#xD;
&#xD;
          -  Age 25+.&#xD;
&#xD;
          -  Stable medications for at least 1 month prior to screening. Central nervous system&#xD;
             (CNS) medications should be stable for 3 months.&#xD;
&#xD;
          -  No evidence of major depression.&#xD;
&#xD;
          -  Informant is available who has frequent contact with the subject (e.g. an average of&#xD;
             10 hours per week or more).&#xD;
&#xD;
          -  Adequate visual and auditory acuity to allow neuropsychological testing.&#xD;
&#xD;
          -  Good general health with no additional diseases expected to interfere with the study.&#xD;
&#xD;
          -  Normal B12, rapid plasma reagin (RPR), and Thyroid Function Tests or without any&#xD;
             clinically significant abnormalities that would be expected to interfere with the&#xD;
             study.&#xD;
&#xD;
          -  ECG without clinically significant abnormalities that would be expected to interfere&#xD;
             with the study.&#xD;
&#xD;
          -  Subject is not pregnant, lactating.&#xD;
&#xD;
          -  Subjects will be taking no drugs with cholinergic properties (e.g donepezil).&#xD;
&#xD;
          -  Agreement not to take other vitamin or supplements other than multivitamins.&#xD;
&#xD;
          -  Negative urine pregnancy test in females.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant neurologic disease such as Alzheimer's disease, Parkinson's disease,&#xD;
             multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain&#xD;
             tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple&#xD;
             sclerosis, or history of significant head trauma followed by persistent neurologic&#xD;
             deficits or known structural brain abnormalities.&#xD;
&#xD;
          -  Active Major depression or another major psychiatric disorder as described in DSM-IV.&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 2 years (DSM IV&#xD;
             criteria).&#xD;
&#xD;
          -  Any significant systemic illness or unstable medical condition which could lead to&#xD;
             difficulty complying with the protocol including:&#xD;
&#xD;
          -  History of myocardial infarction in the past year or unstable or severe cardiovascular&#xD;
             disease including angina or congestive heart failure (CHF) with symptoms at rest.&#xD;
&#xD;
          -  Clinically significant obstructive pulmonary disease or asthma.&#xD;
&#xD;
          -  Clinically significant and unstable gastrointestinal disorder such as ulcer disease or&#xD;
             a history of active or occult gastrointestinal bleeding within two years.&#xD;
&#xD;
          -  Clinically significant laboratory test abnormalities on the battery of screening tests&#xD;
             (hematology, chemistry, urinalysis, ECG).&#xD;
&#xD;
          -  Insulin-requiring diabetes or uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP&gt; 170 or diastolic BP&gt; 100).&#xD;
&#xD;
          -  Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer,&#xD;
             prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A Newhouse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Dept. of Psychiatry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander C Conley, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center Dept. of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Psychiatric Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.vumc.org/ccm/</url>
    <description>Website for the Vanderbilt Center for Cognitive Medicine</description>
  </link>
  <link>
    <url>https://vkc.vumc.org/vkc/</url>
    <description>Website for the Vanderbilt Kennedy Center for research concerning developmental disabilities</description>
  </link>
  <link>
    <url>http://www.somethingextra.org/</url>
    <description>Website for the Down Syndrome Association of Middle Tennessee</description>
  </link>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>February 17, 2022</results_first_submitted>
  <results_first_submitted_qc>May 6, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2022</results_first_posted>
  <last_update_submitted>May 6, 2022</last_update_submitted>
  <last_update_submitted_qc>May 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Paul Newhouse</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Down Syndrome</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Event Related Potential</keyword>
  <keyword>Memory</keyword>
  <keyword>Attention</keyword>
  <keyword>Trisomy 21</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Cognitive Enhancement</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>APOE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01778946/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01778946/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine</title>
          <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg)&#xD;
Moderate Dose Nicotine (14mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine</title>
          <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg)&#xD;
Moderate Dose Nicotine (14mg)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of Nicotine Intervention</title>
        <description>Maximum transdermal nicotine dosage able to be maintained stably by participants.</description>
        <time_frame>1 Month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg); Moderate Dose Nicotine (14mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Nicotine Intervention</title>
          <description>Maximum transdermal nicotine dosage able to be maintained stably by participants.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Improvement - Simple Response Time</title>
        <description>Psychomotor speed was measured by the performance on the CANTAB simple reaction time task</description>
        <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg); Moderate Dose Nicotine (14mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Improvement - Simple Response Time</title>
          <description>Psychomotor speed was measured by the performance on the CANTAB simple reaction time task</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="760.08" spread="542.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737.13" spread="566.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="695.52" spread="344.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="772.79" spread="552.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exploratory - Event-Related Potentials</title>
        <description>The investigators will measure daily low-moderate dose nicotine treatment's changes to electrophysiological markers of memory performance using an incidental memory task. The incidental memory task consists of presenting participants with a series of 60 complex images, 50 of which are presented once, and 10 which are repeated 5 times each. The task measures the presence of the late positive potential (LPP), a positive deflection over the parietal cortex which is elevated for the repeated compared to the singly presented images. The presence of this potential is indicative of improved recognition memory.</description>
        <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg); Moderate Dose Nicotine (14mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory - Event-Related Potentials</title>
          <description>The investigators will measure daily low-moderate dose nicotine treatment's changes to electrophysiological markers of memory performance using an incidental memory task. The incidental memory task consists of presenting participants with a series of 60 complex images, 50 of which are presented once, and 10 which are repeated 5 times each. The task measures the presence of the late positive potential (LPP), a positive deflection over the parietal cortex which is elevated for the repeated compared to the singly presented images. The presence of this potential is indicative of improved recognition memory.</description>
          <units>ÂµV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Repeated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.95" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Repeated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Repeated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 Repeated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Improvement - Continuous Performance Test</title>
        <description>Performance on the Conners' Continuous Performance Test, which is a measure of sustained attention. The main outcome measure was commission errors, which measures attention failures. The commission errors are calculated as T-scores. Higher T-scores indicate worse performance, lower T-scores indicate better performance. Average performance is a score of 50, with a standard deviation of 10.</description>
        <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg); Moderate Dose Nicotine (14mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Improvement - Continuous Performance Test</title>
          <description>Performance on the Conners' Continuous Performance Test, which is a measure of sustained attention. The main outcome measure was commission errors, which measures attention failures. The commission errors are calculated as T-scores. Higher T-scores indicate worse performance, lower T-scores indicate better performance. Average performance is a score of 50, with a standard deviation of 10.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.82" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.23" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.95" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Improvement - Buschke Selective Reminding Task</title>
        <description>Episodic memory performance was assessed by the Buschke Selective Reminding Task. The main outcome metric of this test was the total words correctly recalled.</description>
        <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg); Moderate Dose Nicotine (14mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Improvement - Buschke Selective Reminding Task</title>
          <description>Episodic memory performance was assessed by the Buschke Selective Reminding Task. The main outcome metric of this test was the total words correctly recalled.</description>
          <units>Words Correctly Recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.75" spread="24.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="30.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="33.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="32.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Improvement - Critical Flicker Fusion Task</title>
        <description>Arousal and vigilance were measured by the Critical Flicker Fusion task. The task used at perceptual performance on ascending and descending frequencies of the task.</description>
        <time_frame>4 time-points over the 6-week testing period: at baseline, day 14, day 28 (end of treatment), and 2-weeks post-treatment on day 42.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg); Moderate Dose Nicotine (14mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Improvement - Critical Flicker Fusion Task</title>
          <description>Arousal and vigilance were measured by the Critical Flicker Fusion task. The task used at perceptual performance on ascending and descending frequencies of the task.</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Ascending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Ascending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Ascending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 Ascending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Descending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Descending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Descending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 Descending Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6-weeks</time_frame>
      <desc>Adverse events collected through query of subjects about any new or worsening problems or side effects, conducted at each contact.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nicotine</title>
          <description>Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)&#xD;
All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).&#xD;
Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.&#xD;
All participants will apply a new patch daily for a total of 28 days (1 month)&#xD;
Low Dose Nicotine (7mg)&#xD;
Moderate Dose Nicotine (14mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Newhouse</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6159360928</phone>
      <email>paul.newhouse@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

